Predictmedix To Launch Infectious Diseases Clinical Trial in North American Hospital for FDA Medical Device Classification of Safe Entry Stations
Independent Study for Infectious Diseases Symptom Detection in a Clinical Setting to Provide Additional Third-Party Validation; Prerequisite Ahead of Planned FDA Certification as Class II Medical DeviceTORONTO, ON / ACCESSWIRE / January 26, 2022 / Predictmedix Inc. (CSE:PMED)(OTCQB:PMEDF) ("Predictmedix" or the "Company"), an emerging provider of rapid health screening solutions powered by a proprietary artificial intelligence (AI), today...
Read more








